Safety and efficacy of clopidogrel versus ticagrelor in acute coronary syndrome in the prehospital setting.

Szarpak, Lukasz; Jaguszewski, Milosz J; Pruc, Michal; Malysz, Marek; Gasecka, Aleksandra; Rafique, Zubaid

Szarpak, Lukasz; Jaguszewski, Milosz J; Pruc, Michal; Malysz, Marek; Gasecka, Aleksandra; Rafique, Zubaid.

Afiliação

Szarpak L; Institute of Outcomes Research, Maria Sklodowska-Curie Medical Academy, Warsaw, Poland; Research Unit, Maria Sklodowska-Curie Bialystok Oncology Center, Bialystok, Poland; Research Unit, Polish Society of Disaster Medicine, Warsaw, Poland. Electronic address: lukasz.szarpak@gmail.com.
Jaguszewski MJ; 1st Department of Cardiology, Medical University of Gdansk, Gdansk, Poland.
Pruc M; Research Unit, Polish Society of Disaster Medicine, Warsaw, Poland.
Malysz M; Institute of Outcomes Research, Maria Sklodowska-Curie Medical Academy, Warsaw, Poland.
Gasecka A; 1st Chair and Department of Cardiology, Medical University of Warsaw, Warsaw, Poland.
Rafique Z; Henry JN Taub Department of Emergency Medicine, Baylor College of Medicine, Houston, TX, USA.

Am J Emerg Med ; 56: 351-352, 2022 06.

Article em En | MEDLINE | ID: mdl-34635386

Assuntos

Síndrome Coronariana Aguda; Serviços Médicos de Emergência; Intervenção Coronária Percutânea; Síndrome Coronariana Aguda/tratamento farmacológico; Clopidogrel/uso terapêutico; Humanos; Inibidores da Agregação Plaquetária/efeitos adversos; Ticagrelor/uso terapêutico; Resultado do Tratamento

Palavras-chave

Clopidogrel; Myocardial infarction; Outcome; Prehospital; Ticagrelor

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Serviços Médicos de Emergência / Síndrome Coronariana Aguda / Intervenção Coronária Percutânea Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google